Literature DB >> 31621602

Long-term trends in myocardial sympathetic innervation and function in synucleinopathies.

Guillaume Lamotte1, Courtney Holmes2, Tianxia Wu3, David S Goldstein4.   

Abstract

INTRODUCTION: Parkinson disease (PD), pure autonomic failure (PAF), and multiple system atrophy (MSA) are characterized by intra-cerebral deposition of the protein alpha-synuclein and are termed synucleinopathies. Lewy body synucleinopathies involve decreased cardiac sympathetic innervation and functional abnormalities in residual noradrenergic terminals. This observational, retrospective, cohort study describes long-term trends in indices of cardiac sympathetic innervation and function in synucleinopathies.
METHODS: Patients with PD (N = 31), PAF (N = 9), or MSA (N = 9) underwent repeated 18F-dopamine positron emission tomography (median follow-up 3.5 years). Interventricular septal 18F-dopamine-derived radioactivity 8 min after tracer injection (8' Radioactivity) was used as an index of sympathetic innervation and the slope of mono-exponential decline of radioactivity between 8 and 25 min (k8'-25') as an index of intraneuronal vesicular storage. Healthy volunteers (HVs) (N = 33) and individuals at high risk of PD (N = 15) were controls.
RESULTS: Upon initial evaluation the groups with PD and orthostatic hypotension (OH), PAF, or PD and no OH had low mean 8' Radioactivity compared to HVs (p < 0.0001, p = 0.0002, p = 0.006) and had elevated k8'-25' (p = 0.0007, p = 0.007, p = 0.06). There was no significant difference between MSA and HVs. In PD 8' Radioactivity decreased by a median of 4% per year and did not decrease in MSA. k8'-25' values did not change during follow-up in any group.
CONCLUSIONS: Neuroimaging evidence of decreased vesicular uptake in cardiac sympathetic nerves is present upon initial evaluation of patients with Lewy body synucleinopathies and may provide a biomarker of catecholaminergic dysfunction early in the disease process. Published by Elsevier Ltd.

Entities:  

Keywords:  Fluorodopamine; Multiple system atrophy; Parkinson disease; Pure autonomic failure; Sympathetic nervous system

Mesh:

Substances:

Year:  2019        PMID: 31621602      PMCID: PMC7031858          DOI: 10.1016/j.parkreldis.2019.09.014

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  39 in total

1.  Progressive loss of cardiac sympathetic innervation in Parkinson's disease.

Authors:  Sheng-Ting Li; Raghuveer Dendi; Courtney Holmes; David S Goldstein
Journal:  Ann Neurol       Date:  2002-08       Impact factor: 10.422

2.  Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease.

Authors:  Satoshi Orimo; Takeshi Amino; Yoshinori Itoh; Atsushi Takahashi; Tohru Kojo; Toshiki Uchihara; Kuniaki Tsuchiya; Fumiaki Mori; Koichi Wakabayashi; Hitoshi Takahashi
Journal:  Acta Neuropathol       Date:  2005-06-03       Impact factor: 17.088

3.  Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine.

Authors:  William J Burke; Vijaya B Kumar; Neeraj Pandey; W Michael Panneton; Qi Gan; Mark W Franko; Mark O'Dell; Shu Wen Li; Yi Pan; Hyung D Chung; James E Galvin
Journal:  Acta Neuropathol       Date:  2007-10-27       Impact factor: 17.088

4.  Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders.

Authors:  Ellen Gelpi; Judith Navarro-Otano; Eduardo Tolosa; Carles Gaig; Yaroslau Compta; María Jesús Rey; Maria José Martí; Isabel Hernández; Francesc Valldeoriola; Ramon Reñé; Teresa Ribalta
Journal:  Mov Disord       Date:  2014-01-02       Impact factor: 10.338

5.  Sympathetic cardioneuropathy in dysautonomias.

Authors:  D S Goldstein; C Holmes; R O Cannon; G Eisenhofer; I J Kopin
Journal:  N Engl J Med       Date:  1997-03-06       Impact factor: 91.245

6.  Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder.

Authors:  T Miyamoto; M Miyamoto; Y Inoue; Y Usui; K Suzuki; K Hirata
Journal:  Neurology       Date:  2006-12-26       Impact factor: 9.910

7.  Fate of tritiated 6-fluorodopamine in rats: a false neurotransmitter for positron emission tomographic imaging of sympathetic innervation and function.

Authors:  P C Chang; K Szemeredi; E Grossman; I J Kopin; D S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

8.  Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension.

Authors:  D S Goldstein; C Holmes; Y Sharabi; S Brentzel; G Eisenhofer
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

9.  Cardiac ectopy in chronic autonomic failure.

Authors:  David S Goldstein
Journal:  Clin Auton Res       Date:  2009-12-11       Impact factor: 4.435

10.  MIBG Myocardial Scintigraphy Identifies Premotor PD/DLB During a Negative DAT Scan Period: Second Report.

Authors:  Ryuji Sakakibara; Fuyuki Tateno; Yosuke Aiba; Tsuyoshi Ogata; Masahiko Kishi; Hitoshi Terada; Tsutomu Inaoka; Tomoya Nakatsuka; Katsuyoshi Matsuoka
Journal:  Mov Disord Clin Pract       Date:  2018-11-09
View more
  6 in total

Review 1.  The catecholaldehyde hypothesis: where MAO fits in.

Authors:  David S Goldstein
Journal:  J Neural Transm (Vienna)       Date:  2019-12-05       Impact factor: 3.575

2.  Modeling the Progression of Cardiac Catecholamine Deficiency in Lewy Body Diseases.

Authors:  David S Goldstein; Mark J Pekker; Patti Sullivan; Risa Isonaka; Yehonatan Sharabi
Journal:  J Am Heart Assoc       Date:  2022-05-27       Impact factor: 6.106

3.  Cardiac 18F-Dopamine PET Distinguishes PD with Orthostatic Hypotension from Parkinsonian MSA.

Authors:  Abhishek Lenka; Guillaume Lamotte; David S Goldstein
Journal:  Mov Disord Clin Pract       Date:  2021-03-23

4.  Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies.

Authors:  David S Goldstein; Patti Sullivan; Courtney Holmes; Guillaume Lamotte; Abhishek Lenka; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2021-05-21       Impact factor: 5.546

Review 5.  The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Authors:  David S Goldstein
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

Review 6.  Cardiac Changes in Parkinson's Disease: Lessons from Clinical and Experimental Evidence.

Authors:  Lorena Cuenca-Bermejo; Pilar Almela; Javier Navarro-Zaragoza; Emiliano Fernández Villalba; Ana-María González-Cuello; María-Luisa Laorden; María-Trinidad Herrero
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.